Literature DB >> 8432597

Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children.

S J Cryz1, N Vanprapar, U Thisyakorn, T Olanratmanee, G Losonsky, M M Levine, S Chearskul.   

Abstract

Salmonella typhi Ty21a vaccine in a liquid formulation was evaluated in 634 Thai children 2 to 6 years of age. The seroconversion rate was 69% for those who received vaccine versus 14% for those who received placebo (P < 0.005). The immune responses among vaccine recipients ranged from 60% in 3-year-olds to 81% for 6-year-olds.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8432597      PMCID： PMC302854          DOI： 10.1128/iai.61.3.1149-1151.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  10 in total

1.  Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial.

Authors:  M M Levine; C Ferreccio; S Cryz; E Ortiz
Journal:  Lancet       Date:  1990-10-13       Impact factor: 79.321

2.  Epidemic multiresistant enteric fever in eastern India.

Authors:  A C Anand; V K Kataria; W Singh; S K Chatterjee
Journal:  Lancet       Date:  1990-02-10       Impact factor: 79.321

3.  Characteristics of humoral and cellular immunity to Salmonella typhi in residents of typhoid-endemic and typhoid-free regions.

Authors:  J R Murphy; S Baqar; C Muñoz; L Schlesinger; C Ferreccio; A A Lindberg; S Svenson; G Losonsky; F Koster; M M Levine
Journal:  J Infect Dis       Date:  1987-12       Impact factor: 5.226

4.  Summary of an international workshop on typhoid fever.

Authors:  R Edelman; M M Levine
Journal:  Rev Infect Dis       Date:  1986 May-Jun

5.  Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine.

Authors:  C H Simanjuntak; F P Paleologo; N H Punjabi; R Darmowigoto; H Totosudirjo; P Haryanto; E Suprijanto; N D Witham; S L Hoffman
Journal:  Lancet       Date:  1991-10-26       Impact factor: 79.321

6.  Typhoid and paratyphoid fever in 192 hospitalized children in Thailand.

Authors:  U Thisyakorn; P Mansuwan; D N Taylor
Journal:  Am J Dis Child       Date:  1987-08

Review 7.  Progress in vaccines against typhoid fever.

Authors:  M M Levine; C Ferreccio; R E Black; C O Tacket; R Germanier
Journal:  Rev Infect Dis       Date:  1989 May-Jun

8.  Immunogenicity of Salmonella typhi Ty21a vaccine for young children.

Authors:  J R Murphy; L Grez; L Schlesinger; C Ferreccio; S Baqar; C Muñoz; S S Wasserman; G Losonsky; J G Olson; M M Levine
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

9.  Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans.

Authors:  M M Levine; D Herrington; J R Murphy; J G Morris; G Losonsky; B Tall; A A Lindberg; S Svenson; S Baqar; M F Edwards
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

10.  Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules.

Authors:  R Black; M M Levine; C Young; J Rooney; S Levine; M L Clements; S O'Donnell; T Hugues; R Germanier
Journal:  Dev Biol Stand       Date:  1983
  10 in total
  18 in total

Review 1.  Vaccination against Salmonella Infection: the Mucosal Way.

Authors:  Rémi Gayet; Gilles Bioley; Nicolas Rochereau; Stéphane Paul; Blaise Corthésy
Journal:  Microbiol Mol Biol Rev       Date:  2017-06-14       Impact factor: 11.056

Review 2.  Live attenuated vaccines for invasive Salmonella infections.

Authors:  Sharon M Tennant; Myron M Levine
Journal:  Vaccine       Date:  2015-04-19       Impact factor: 3.641

3.  Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella typhi Ty21a and Vibrio cholerae CVD 103-HgR live oral vaccines.

Authors:  H Kollaritsch; E Furer; C Herzog; G Wiedermann; J U Que; S J Cryz
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

4.  Mucosal priming of newborn mice with S. Typhi Ty21a expressing anthrax protective antigen (PA) followed by parenteral PA-boost induces B and T cell-mediated immunity that protects against infection bypassing maternal antibodies.

Authors:  Karina Ramirez; Yanina Ditamo; James E Galen; Les W J Baillie; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-07-07       Impact factor: 3.641

5.  Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains.

Authors:  Sharon M Tennant; Jin-Yuan Wang; James E Galen; Raphael Simon; Marcela F Pasetti; Orit Gat; Myron M Levine
Journal:  Infect Immun       Date:  2011-08-01       Impact factor: 3.441

Review 6.  Immunology of gut mucosal vaccines.

Authors:  Marcela F Pasetti; Jakub K Simon; Marcelo B Sztein; Myron M Levine
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

7.  Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi.

Authors:  Janet C Lindow; Kelly A Fimlaid; Janice Y Bunn; Beth D Kirkpatrick
Journal:  Infect Immun       Date:  2011-05-31       Impact factor: 3.441

8.  Safety and immunogenicity of a live oral bivalent typhoid fever (Salmonella typhi Ty21a)-cholera (Vibrio cholerae CVD 103-HgR) vaccine in healthy adults.

Authors:  S J Cryz; J U Que; M M Levine; G Wiedermann; H Kollaritsch
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

9.  Genetic control of antibody responses induced against an antigen delivered by recombinant attenuated Salmonella typhimurium.

Authors:  C Fayolle; D O'Callaghan; P Martineau; A Charbit; J M Clément; M Hofnung; C Leclerc
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

Review 10.  Vaccination against typhoid fever: present status.

Authors:  B Ivanoff; M M Levine; P H Lambert
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.